ICH Q2(R2) and Q14: new analytical validation and development guidelines
| Document | ICH Q2(R2) Validation of Analytical Procedures and ICH Q14 Analytical Procedure Development, Final Versions adopted 1 November 2023 ↗ |
|---|---|
| Issued by | ICH |
| Issued | 1 Nov 2023 |
In short: ICH adopted Q2(R2) (validation) and the new Q14 (development) as final versions on 1 November 2023. Q2(R2) is a complete revision of Q2(R1), aligned with Q14, and covers more recent techniques including multivariate procedures.
What changed
- Q2(R2)‘s document history describes it as a complete revision to include more recent applications of analytical procedures and align with Q14. It replaces the earlier Q2(R1) text and methodology.
- Scope: release and stability testing of commercial drug substances and products. It can also apply to other procedures in the control strategy using a risk-based approach.
- Validation is tied to the analytical procedure lifecycle. Suitable data from development (Q14) can be used as validation data, and an established platform procedure used for a new purpose may have abbreviated validation if justified.
- Revalidation after changes, method transfer and co-validation are addressed; science and risk-based principles justify which performance characteristics need revalidation.
- Q2(R2) includes a section on demonstrating stability-indicating properties and one on multivariate procedures.
- Q14 describes minimal and enhanced approaches to development, the analytical target profile, established conditions and lifecycle management of post-approval changes. The minimal approach remains acceptable.
Who it affects
Analytical development and QC labs, and regulatory affairs teams of firms filing registration applications.
Key dates
- 1 November 2023: Step 4 adoption (stated on the guideline cover pages).
- Regional implementation dates were not checked.
What to do now
- Review method validation SOPs and templates against Q2(R2) terminology and the range, specificity, accuracy and precision sections.
- Decide per method whether a minimal or enhanced development approach applies, and record development data so it can support validation (example in-house approach).
- Revisit your change and transfer procedures for revalidation decisions.
Related reading: Quality management system for laboratory management in pharma, Why Stability Testing is So Important.